CN116059293B - Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN116059293B CN116059293B CN202211627569.1A CN202211627569A CN116059293B CN 116059293 B CN116059293 B CN 116059293B CN 202211627569 A CN202211627569 A CN 202211627569A CN 116059293 B CN116059293 B CN 116059293B
- Authority
- CN
- China
- Prior art keywords
- cilia
- preparation
- group
- parts
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 230000009798 acute exacerbation Effects 0.000 title claims abstract description 22
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 31
- 210000004081 cilia Anatomy 0.000 claims abstract description 116
- 108090000976 Aquaporin 5 Proteins 0.000 claims abstract description 23
- 102000004392 Aquaporin 5 Human genes 0.000 claims abstract description 22
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims abstract description 15
- 230000006378 damage Effects 0.000 claims abstract description 15
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 13
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 11
- 102000004243 Tubulin Human genes 0.000 claims abstract description 10
- 108090000704 Tubulin Proteins 0.000 claims abstract description 10
- 208000036815 beta tubulin Diseases 0.000 claims abstract description 9
- 210000002175 goblet cell Anatomy 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 210000000981 epithelium Anatomy 0.000 claims abstract description 7
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 claims abstract description 6
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 claims abstract 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims abstract 2
- 102100031083 Uteroglobin Human genes 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 86
- 239000000243 solution Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 34
- 230000002829 reductive effect Effects 0.000 claims description 30
- 238000005303 weighing Methods 0.000 claims description 27
- 239000010440 gypsum Substances 0.000 claims description 24
- 229910052602 gypsum Inorganic materials 0.000 claims description 24
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 19
- 238000005507 spraying Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920002472 Starch Polymers 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- 235000019698 starch Nutrition 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 16
- 240000000249 Morus alba Species 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 15
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 14
- 241001522129 Pinellia Species 0.000 claims description 14
- 235000017617 Lonicera japonica Nutrition 0.000 claims description 12
- 244000167230 Lonicera japonica Species 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- 235000011477 liquorice Nutrition 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 11
- 241000219061 Rheum Species 0.000 claims description 11
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 235000003130 Arctium lappa Nutrition 0.000 claims description 9
- 235000008078 Arctium minus Nutrition 0.000 claims description 9
- 241000244269 Peucedanum Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 241000218671 Ephedra Species 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 244000144725 Amygdalus communis Species 0.000 claims description 4
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241000935235 Fritillaria meleagris Species 0.000 claims description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 3
- 240000004980 Rheum officinale Species 0.000 claims description 3
- 235000008081 Rheum officinale Nutrition 0.000 claims description 3
- 230000035559 beat frequency Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 244000018633 Prunus armeniaca Species 0.000 claims description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- -1 tincture Substances 0.000 claims description 2
- 240000005528 Arctium lappa Species 0.000 claims 3
- 229940098465 tincture Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 28
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000010349 pulsation Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 66
- 210000004072 lung Anatomy 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical group NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 29
- 210000003097 mucus Anatomy 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 25
- 239000002609 medium Substances 0.000 description 23
- 239000002158 endotoxin Substances 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 17
- 102100022496 Mucin-5AC Human genes 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 210000003437 trachea Anatomy 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000779 smoke Substances 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000004688 microtubule Anatomy 0.000 description 7
- 241000208843 Arctium Species 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 210000003456 pulmonary alveoli Anatomy 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 238000004627 transmission electron microscopy Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000254 ciliated cell Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 229960005174 ambroxol Drugs 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000005062 tracheal ring Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000004879 pulmonary tissue Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 230000000420 mucociliary effect Effects 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 102100025802 Cystin-1 Human genes 0.000 description 1
- 101710106195 Cystin-1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010034536 Mucin 5AC Proteins 0.000 description 1
- 102000009616 Mucin 5AC Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001076395 Rattus norvegicus Interleukin-13 Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- BBKFSSMUWOMYPI-UHFFFAOYSA-N gold palladium Chemical compound [Pd].[Au] BBKFSSMUWOMYPI-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000017804 lesions in lung Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and particularly discloses application of a traditional Chinese medicine composition in preparing a medicine for treating acute exacerbation phase of chronic obstructive pulmonary disease, and researches prove that the medicine can inhibit application of Clara cells to goblet cell differentiation medicines, increase application of CCSP protein expression medicines, promote AQP5 protein or AQP5 mRNA expression and reduce MMP-9 or IL-13 factor expression; it has also been demonstrated that the medicament of the invention can protect the cilia structure of airway epithelium, in particular in increasing cilia length, increasing cilia number, up-regulating beta-Tubulin IV protein expression, improving cilia direction, protecting cilia from ultrastructural damage; protecting airway cilia function and increasing cilia pulsation frequency.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for treating acute exacerbation of chronic obstructive pulmonary disease.
Background
Acute exacerbation of chronic obstructive pulmonary disease (Acute exacerbations of chronic obstructive pulmonary disease, AECOPD) refers to acute exacerbation of respiratory symptoms in a patient's COPD progression, resulting in the need for additional treatment. AECOPD can be caused by a number of factors, commonly upper respiratory tract and tracheal, bronchial infections. Acute exacerbations can be caused by physical and chemical factors such as smoking, air pollution, inhaled allergens, air temperature changes, etc., and irregular or interrupted treatment in the stationary phase. The main symptoms of AECOPD are exacerbation of shortness of breath, frequent wheezing, chest distress, cough aggravation, increased sputum volume, changes in sputum color and/or viscosity, fever, etc., and symptoms of general discomfort, insomnia, somnolence, fatigue, depression, mental disturbance, etc. can also appear. Patient exercise endurance decline, fever and/or chest X-ray imaging abnormalities may be signs of COPD exacerbation. Increased sputum and appearance of purulent sputum often suggest bacterial infection.
Airway mucus hypersecretion is an important pathological feature of AECOPD, an independent risk factor for AECOPD exacerbation and death. Airway mucus is usually the first line of defense of the respiratory tract, and can remove harmful substances, keep the airway moist, and protect the surface of the respiratory tract of a human body from being damaged by inhalation of the harmful substances. AECOPD interacts with airway mucus hypersecretion, which alters the airway microenvironment, providing favorable conditions for infection by microorganisms such as viruses, bacteria, etc. in the airways, making AECOPD infection difficult to control. While pathogenic microbial infection and its subsequent inflammatory products further cause mucus hypersecretion, forming a vicious circle, leading to AECOPD airway obstruction, airflow limitation, and reduced lung function. Airway hypersecreting patients the risk of AECOPD death is 3.5 times that of non-airway hypersecreting patients. Improving airway mucus hypersecretion can effectively improve the curative effect of AECOPD. Thus, inhibition of airway mucus hypersecretion is of clinical importance in the treatment of AECOPD.
The mucociliary clearance defense mechanism of the respiratory tract consists of mucus and cilia. Cilia are widely present in the human respiratory tract and are a major component of the mucociliary clearance system. Cilia regularly continue to oscillate in the mucus-fiber blanket, pushing harmful particles and pathogens out of the airways. Physiological change characteristics of AECOPD include mucus hypersecretion and cilia dysfunction. Inflammation caused by an acute episode can alter Ciliated Beat Frequency (CBF) by inflammatory and/or epithelial cells releasing mediators or causing cilia injury, epithelial cell loss and basement membrane injury. CBF and wave patterns are important biological indicators of epithelial cell function and may be altered during an acute episode, resulting in secretion accumulation and impaired beating. Structure-function studies help to determine the ciliary target sites involved in regulating cilia beat, and cilia characteristics that may lead to pulmonary disease include cilia function (cilia beat frequency-CBF), cilia length, cilia density, and cilia structure, which can alter CBF and motor quality. Random cilia orientation has also been reported as a possible cause of respiratory disease. Clinically, an expectorant is commonly used to treat airway mucus hypersecretion in combination with glucocorticoids and antibiotics. Although expectorants and glucocorticoids temporarily alleviate the symptoms of airway mucus hypersecretion, they do not fundamentally reduce the production of sputum. At the same time, bacterial resistance and double infection by antibiotics prevent disease prognosis. Due to excessive injury to airway mucus secretion, it is necessary to administer targeted therapies. However, the pathophysiological mechanisms of mucus-scavenging obstruction may be different for each disease, and therefore there may be no single treatment available in the area of respiratory obstruction, and there is a need to find drugs that are effective in improving airway mucus hypersecretion.
Disclosure of Invention
Aiming at the technical problems existing in the acute exacerbation stage of the existing chronic obstructive pulmonary disease, the invention provides application of a traditional Chinese medicine composition in preparing a medicine for treating the acute exacerbation stage of the chronic obstructive pulmonary disease.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
the application of a traditional Chinese medicine composition in preparing a medicine for treating acute exacerbation of chronic obstructive pulmonary disease is provided, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 52-86 of ephedra; gypsum 194-324; fructus forsythiae 194-324; 78-130 parts of radix scutellariae; white mulberry root bark 194-324; 78-130 parts of fried bitter apricot kernel; 78-130 parts of radix peucedani; 78-130 parts of pinellia ternate; 78-130 parts of dried orange peel; 78-130 parts of fritillary bulb; 78-130 parts of burdock; 78-130 parts of lonicera japonica; 39-65 parts of rheum officinale; radix Platycodi 46-76; 39-65 parts of liquorice.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 52; gypsum 324; fructus forsythiae 194; radix Scutellariae 78; cortex Mori 194; parching semen Armeniacae amarum 130; radix Peucedani 78; pinellia ternate 130; dried orange peel 78; bulbus Fritillariae Thunbergii 78; fructus Arctii 130; flos Lonicerae 130; rhubarb 39; radix Platycodi 76; licorice 65.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 86; gypsum 194; fructus forsythiae 324; radix Scutellariae 130; cortex Mori 324; parching semen Armeniacae amarum 78; radix Peucedani 130; pinellia tuber 78; dried orange peel 130; bulbus Fritillariae Thunbergii 130; burdock 78; flos Lonicerae 78; rhubarb 65; radix Platycodi 46; licorice 39.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: ephedra 69; gypsum 259; fructus forsythiae 259; radix Scutellariae 104; cortex Mori 259; parching semen Armeniacae amarum 104; radix Peucedani 104; pinellia ternate 104; dried orange peel 104; bulbus Fritillariae Thunbergii 104; fructus Arctii 104; flos Lonicerae 104; rhubarb 52; radix Platycodi 61; licorice 52.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 55; gypsum 254; fructus forsythiae 318; radix Scutellariae 107; white mulberry root bark 203; a fried bitter almond 107; radix Peucedani 82; pinellia ternate 105; dried orange peel 84; bulbus Fritillariae Thunbergii 125; burdock 122; flos Lonicerae 113; rhubarb 42; radix Platycodi 60; licorice root 50.
The traditional Chinese medicine composition mainly comprises ephedra, gypsum, fructus forsythiae, radix scutellariae, cortex mori radicis and the like, plays the integral regulation advantages of the compound traditional Chinese medicine, and has obvious curative effects on acute exacerbation stage of chronic obstructive pulmonary disease through animal verification by organically combining the functions of eliminating pathogenic factors, relieving symptoms and regulating immunity.
The traditional Chinese medicine can be replaced by traditional Chinese medicines with the same or similar effects, and the traditional Chinese medicines can be processed according to national traditional Chinese medicine processing standards or Chinese medicine dictionary.
The active ingredients of the traditional Chinese medicine composition are prepared by the following steps:
A. Weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 40-70% ethanol for 2 times, each for 1-4 hr, adding 8-10 times of the extractive solution for the first time and 6-9 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.14-1.16 at 60deg.C;
C. weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for two times, 1-4 hours each time, adding 9-11 times of the weight of the first time and 7-9 times of the weight of the second time, merging decoction, filtering, decompressing filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.14-1.16 measured by heat at 60 ℃, merging with the clear paste obtained in the step B for standby;
the fine powder obtained in the step A and the combined fluid extract obtained in the step C jointly form the active ingredient of the pharmaceutical composition. The medicament of the invention is in the dosage forms of capsules, tablets, powder, granules, oral liquid, soft capsules, pills, tinctures, syrups, suppositories, gels, sprays or injections.
To enable the above dosage forms, pharmaceutically acceptable excipients are added in the preparation of these dosage forms, for example: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrices, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, and the like; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, crosslinked sodium carboxymethyl cellulose, and the like; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the binder includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, etc.; the flavoring agent comprises: sweetener and various flavors; the preservative comprises: nipagin, benzoic acid, sodium benzoate, sorbic acid and salts thereof, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil and the like; the matrix comprises: PEG6000, PEG4000, insect wax, and the like.
Wherein the tablet is prepared by the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 40-70% ethanol for 2 times, each for 1-4 hr, adding 8-10 times of the extractive solution for the first time and 6-9 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.14-1.16 at 60deg.C;
C. weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for two times, 1-4 hours each time, adding 9-11 times of the weight of the first time and 7-9 times of the weight of the second time, merging decoction, filtering, decompressing filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.14-1.16 measured by heat at 60 ℃, merging with the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
200-355 of the spray powder obtained in the step D; the fine powder obtained in the step A is 54-145; 10-15.5 parts of sodium carboxymethyl starch; microcrystalline cellulose 7-12; 1.5 to 3.5 percent of magnesium stearate, adding starch, and preparing tablets according to a conventional preparation method.
The preparation method of the preferred tablet comprises the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 50% ethanol for 2 times and 3 hr each time, adding 10 times of the extractive solution for the first time and 6 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.15 at 60deg.C;
C. weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for 2 hours each time, adding 10 times of the weight for the first time and 7 times of the weight for the second time, merging the decoctions, filtering, decompressing the filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.15 measured by heat at 60 ℃, merging the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
step D, spraying powder 282.6; the fine powder 101 obtained in the step A; 12.5 parts of sodium carboxymethyl starch; microcrystalline cellulose 9.0; 2.25 parts of magnesium stearate, adding starch, and making into tablet by conventional preparation method.
The preparation method of other dosage forms of the medicine comprises the following steps: the raw materials are weighed according to the proportion and prepared by adopting a conventional preparation method, for example, a preparation process recorded in Fan Biting traditional Chinese medicine pharmacy (1 st edition of 1997 of Shanghai science publishing Co., ltd.) is adopted to prepare a pharmaceutically acceptable conventional dosage form.
The traditional Chinese medicine composition is used for treating acute exacerbation of chronic obstructive pulmonary disease, and is preferably used for inhibiting Clara cells from differentiating into goblet cells, increasing CCSP protein expression, promoting AQP5 protein or AQP5 mRNA expression, reducing MMP-9 or IL-13 factor expression and treating lung injury.
The traditional Chinese medicine composition is applied to treating acute exacerbation of chronic obstructive pulmonary disease, preferably to drugs for protecting cilia structures of airway epithelium, and particularly to drugs for increasing cilia length, increasing cilia quantity, up-regulating beta-Tubulin IV protein expression, improving cilia direction and protecting cilia ultrastructural damage.
The traditional Chinese medicine composition is applied to the treatment of acute exacerbation stage of chronic obstructive pulmonary disease, preferably to the drug for protecting the cilia function of the airway, in particular to the drug for increasing the cilia beating frequency.
The traditional Chinese medicine composition is applied to treating acute exacerbation of chronic obstructive pulmonary disease, preferably to improving airway mucus hypersecretion of patients.
Drawings
Fig. 1: lung tissue morphology (HE staining, ×200) of rats of each group;
fig. 2: comparison of average alveolar intercept (MLI) and average alveolar number (MAN) of groups of ratsN=5), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.05, and the # P is less than 0.01; comparison with the Positive group of drugs DeltaDeltaP<0.01;
Fig. 3: positive expression of rat airway goblet cells (AB-PAS staining, ×200) in each group;
fig. 4: comparison of positive relative coloring area of AB-PAS of airway of rats in each groupN=5), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.01; delta.P compared to ambroxol group<0.01;
Fig. 5: positive expression of CCSP in the airways of rats of each group (immunofluorescent staining, ×200);
fig. 6: lung tissue MUC5AC positive expression (immunohistochemical staining, ×200) in each group of rats;
Fig. 7: the lung tissue of each group of rats expressed AQP5 positively (immunohistochemical staining, ×200);
fig. 8: positive expression comparison of MUC5AC and AQP5 in lung tissue of ratsN=5), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.05 compared to the normal group; comparing to the model group, #P < 0.05; compared with ambroxol group, deltaP<0.05;
Fig. 9: comparison of MUC5AC and AQP5 mRNA expression in Lung tissue of rats of each groupN=4), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.05 compared to the normal group; comparing to the model group, #P < 0.05;
fig. 10: TNF-alpha, IL-1 beta and MMP-9 content in BALF of each group of rats is comparedpg/mL, n=8), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.01; delta.P compared to ambroxol group<0.01;
Fig. 11: IL-13 content comparison in serum of rats of each grouppg/mL, n=8), a. Normal group; B. a model group; lhqk low dose group; dose group in lhqk; lhqk high dose group; F. ambroxol group. P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.01; compared with ambroxol group, deltaP <0.05,△△ P<0.01;
Fig. 12: a is LHQK, which improves the degree of lung parenchymal injury in AECOPD rats, HE stains lung tissue (x 40). Red arrows show alveolar fusion and inflammatory cell infiltration. B Mean Lung Intercept (MLI), data shown as mean ± standard deviation (n=5), P <0.01 compared to control group, #p <0.01 compared to cs+lps group;
fig. 13: a airway H & E staining to assess airway epithelial cilia morphology change map, (x 40); b scanning electron microscope (X200, X1500, X6000);
fig. 14: a is SEM longitudinal section (x 12000); b cilia length (μm), data expressed as mean ± standard deviation, # P <0.01 compared to control group, # P <0.01 compared to cs+lps group;
fig. 15: detecting the expression of cilia related protein beta-Tubulin IV by adopting an immunofluorescence method; B-C Western Blot detects the expression of cilia-associated protein beta-tubulin IV (cilia-specific marker) in the trachea. Data are expressed as mean ± standard deviation, # P <0.01 compared to control group, # P <0.05 compared to cs+lps group;
fig. 16: a, analyzing the tracheal ring CBF by Image J software, wherein an arrow indicates one cilia swing; b tracheal rings CBF (n=3). P <0.01 compared to control group, #p <0.01 compared to cs+lps group; c in vitro ciliated cells CBF (n=3)..p <0.01 compared to control group, #p <0.01 compared to cs+lps group;
Fig. 17: a is TEM (x 2500). DM is peripheral microtubule, CM is central microtubule, green arrow indicates ciliated membrane rupture and disintegration; the black arrows B indicate microtubule displacement, the red arrows indicate ciliated membrane vesicles, and the blue arrows indicate large cilia; c cilia ultrastructural anomaly rate;
fig. 18: the TEM (x 15000) line is the line through the central microtubule, called the cilia axis, a line perpendicular to the cilia axis also pointing in the direction of cilia beat.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
Prescription:
52 g of ephedra; 324 grams of gypsum; 194 g of weeping forsythia; 78 g of baikal skullcap root; 194 g of white mulberry root-bark; 130 g of fried bitter almond; radix peucedani 78 g; 130 g of pinellia ternate; 78 g of dried orange peel; 78 g of fritillary bulb; 130 g of burdock; 130 g of lonicera japonica; 39 g of rheum officinale; 76 g of platycodon grandiflorum; 65 g of liquorice.
The preparation method comprises the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 50% ethanol for 2 times and 3 hr each time, adding 10 times of the extractive solution for the first time and 6 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.15 at 60deg.C;
C. Weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for 2 hours each time, adding 10 times of the weight for the first time and 7 times of the weight for the second time, merging the decoctions, filtering, decompressing the filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.15 measured by heat at 60 ℃, merging the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
step D, spraying powder 282.6; the fine powder 101 obtained in the step A; 12.5 parts of sodium carboxymethyl starch; microcrystalline cellulose 9.0; 2.25 parts of magnesium stearate, adding starch, and making into tablet by conventional preparation method.
Example 2
Prescription:
herba Ephedrae 86; gypsum 194; fructus forsythiae 324; radix Scutellariae 130; cortex Mori 324; parching semen Armeniacae amarum 78; radix Peucedani 130; pinellia tuber 78; dried orange peel 130; bulbus Fritillariae Thunbergii 130; burdock 78; flos Lonicerae 78; rhubarb 65; radix Platycodi 46; licorice 39.
The preparation method comprises the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 40% ethanol for 2 times and 4 hr each time, adding 8 times of the extractive solution for the first time and 9 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.14 at 60deg.C;
C. Weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for two times, wherein the amount of the water is 9 times for each time for 4 hours, the amount of the water is 7 times for the first time, the decoctions are combined, filtered, the filtrate is decompressed and ethanol is recovered, and the filtrate is concentrated to the clear paste with the relative density of 1.16 measured by heat at 60 ℃ and is combined with the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
step D, spraying powder 200; the fine powder 145 obtained in step a; sodium carboxymethyl starch 10; microcrystalline cellulose 12; 1.5, adding starch, and making into tablet by conventional method.
Example 3
Prescription:
ephedra 69; gypsum 259; fructus forsythiae 259; radix Scutellariae 104; cortex Mori 259; parching semen Armeniacae amarum 104; radix Peucedani 104; pinellia ternate 104; dried orange peel 104; bulbus Fritillariae Thunbergii 104; fructus Arctii 104; flos Lonicerae 104; rhubarb 52; radix Platycodi 61; licorice 52.
The preparation method comprises the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 70% ethanol for 2 times (1 hr each time), adding 10 times of the extractive solution for the first time, adding 6 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, and concentrating to obtain fluid extract with relative density of 1.16 at 60deg.C;
C. Weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for two times, 1 hour each time, adding 11 times of the weight for the first time, adding 7 times of the weight for the second time, merging decoction, filtering, decompressing filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.14 measured by heat at 60 ℃, merging with the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
step D, spraying powder 355; the fine powder 54 obtained in the step A; 15.5 parts of sodium carboxymethyl starch; microcrystalline cellulose 7; 3.5, adding starch, and making into tablet by conventional method.
Example 4:
the formula of the raw materials is as follows:
herba Ephedrae 55; gypsum 254; fructus forsythiae 318; radix Scutellariae 107; white mulberry root bark 203; a fried bitter almond 107; radix Peucedani 82; pinellia ternate 105; dried orange peel 84; bulbus Fritillariae Thunbergii 125; burdock 122; flos Lonicerae 113; rhubarb 42; radix Platycodi 60; licorice root 50.
The preparation method comprises the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 60% ethanol for 2 times and 2 hr each time, adding 9 times of the extractive solution for the first time and 7 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.15 at 60deg.C;
C. Weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the formula, adding water and decocting for 2.5 hours each time, adding 10 times of the weight of the mixture for the first time, adding 7 times of the weight of the mixture for the second time, merging the decoctions, filtering, decompressing the filtrate, recovering ethanol, concentrating the filtrate to obtain clear paste with the relative density of 1.14 measured by heat at 60 ℃, merging the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
the spray powder 300 obtained in the step D; the fine powder 132 obtained in step a; sodium carboxymethyl starch 14; microcrystalline cellulose 10.2; magnesium stearate 1.75, adding starch, and making into tablet by conventional method.
Experimental example 1:
to elucidate the effect of the drug of the present invention on improving the acute exacerbation phase of chronic obstructive pulmonary disease, the following experimental study was conducted using a tablet (hereinafter referred to as the drug of the present invention or LHQK) prepared in the same manner as in example 1.
1 Material
1.1 animals
150 SPF-class male Wistar rats, 5-6 weeks old, have a mass (200+ -20) g, and are purchased from Beijing Veitz laboratory animal technologies Co., ltd, animal quality certification No. 110011210114505818, certification No. SCXK [ Beijing ]2021-0011, approved by the national institutes of medicine, hebei, and No. N2021162.
1.2 drugs and Agents
LHQK (shijia, division of the kaolin pharmaceutical industry); ambroxol hydrochloride tablet (Shandong Yuxin pharmaceutical Co., ltd., batch number H20163194); lipopolysaccharide (LPS, sigma Co., USA); AB-PAS staining kit (Beijing Solaro Co., ltd., product number G1285); MUC5AC antibody (Abcam, UK, cat# ab 3649); AQP5 antibody (Abcam, uk, cat No. ab 78486); CCSP antibody (Abcam, uk, cat No. ab 213203); fluorescent secondary antibodies (Abcam, UK, cat# ab 150064); immunohistochemical staining kit (Beijing Zhonghua Jinqiao Co., ltd., product number PV-9001); rat tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), matrix metalloproteinase-9 (MMP-9) enzyme-linked immunosorbent assay (ELISA) kit (Proteintech, USA, cat# KE20001, KE20005, KE20006, respectively); rat interleukin-13 (IL-13) enzyme-linked immunosorbent assay (ELISA) kit (Wuhan Yillere Corp., cat# E-EL-R0563 c); reverse transcription kit, fluorescent quantitative kit (TaKaRa Co., japan); rat GAPDH, MUC5AC, AQP5 primer (Beijing Ding Guo Changsheng biotechnology Co., ltd.)
1.3 instruments
ME104E analytical balance (meltrefoil torrado, usa); TEC5 type Tissue embedding machine (sakura Tissue-Tek Co., japan); RM2235 rotary paraffin microtome, DM6000b optical microscope, LSM710 laser confocal fluorescence microscope (Leica company, germany); synergy 4-type multifunctional microplate reader (Bio Tek company, usa); HZ-2011KC type constant temperature shaking table (Tai cang Hua Li to experimental facilities Co., ltd.); 7900HT type real-time fluorescence quantitative PCR instrument (ABI company of America)
2. Method of
2.1 AECOPD rat model preparation
A method of smoke combined airway instillation Lipopolysaccharide (LPS) is adopted to prepare an AECOPD airway mucus high secretion rat model. LPS (1 mg/kg body weight) was instilled into the trachea of rats 24h before the experiment was carried out on days 1 and 14 and the materials were obtained, the same amount of physiological saline was instilled into the blank group (no smoking was carried out on the instillation day), rats were placed in a self-made smoking box (100 cm. Times.70 cm. Times.40 cm) for smoking on day 2, the smoke concentration was 180mg/m3, and smoking was carried out once every day and afternoon for 1h (15-20 min ventilation every 1 h), 40 cigarettes/h and 5 d/week. After smoking and administration for 12 weeks, the model was evaluated for pathology and the materials were anesthetized.
2.2 grouping and administration
150 rats were randomly assigned to a blank (Control), model (Model), low-dose (LHQK-L), medium-dose (LHQK-M), high-dose (LHQK-H) and Ambroxol (Ambroxol) group after one week of adaptive rearing. The low, medium and high doses of the medicine of the invention are respectively given with 1.47, 2.93 and 5.86 g crude drug/(kg.d) suspension for gastric lavage, wherein the medium dose is equivalent to 8 times of clinical dosage of people. Ambroxol group was given 30 mg/(kg.d) of ambroxol suspension and the model group was given an equivalent dose of 0.5% sodium carboxymethyl cellulose (CMC) solution for 12 weeks. The blank group was fed with water freely. The equivalent dose coefficient conversion formula was used to calculate the lavage dose [ [ i ] ] as D rat = D human x (HI rat/HI human) x (W rat/W human) 2/3, D as dose, HI as body size coefficient, W as body mass.
2.3 detection index
2.3.1 general observations of rats
The growth condition and activity of rats in each group are observed, and the skin and hair has smooth color, mental state, cough, asthma, etc.
2.3.2 HE staining for observing lung tissue pathology
Rat lung tissue was fixed with 4% paraformaldehyde, paraffin embedded, tissue sections were then HE stained and examined under a microscope for pathological changes such as alveolar size, structure and inflammatory cell infiltration. 3 alveolar visual field pictures are randomly cut from each lung tissue slice, a cross is drawn in the center of the picture, the alveolar number (Na) and the alveolar septum number (Ns) of each visual field are calculated, the length (L) and the area (S) are measured, and the calculation formula is as follows: average alveolar intercept (mean linear intercept, MLI) (μm) =l/Ns, average alveolar number (mean alveolar number, MAN) (/ mm) 2 )=Na/S。
2.3.3 AB-PAS staining for observing rat airway goblet cell metaplasia and mucus secretion
Dewaxing rat lung tissue slices to water, adding aliskirin blue dye solution, dyeing for 15 min, washing with distilled water for 3 times each for 2 min, oxidizing with 1% periodate aqueous solution for 5 min, washing with distilled water for 3 times, and dyeing with Schiff solution for 15 min. Flushing with running water for 10 min; hematoxylin staining for 1 min, and washing; differentiating the acidic differentiation liquid for 2-5s, and washing with water; returning the Scott blue-dissolving liquid to blue for 3min, and washing with water for 3min; dehydrated in absolute ethyl alcohol, transparent xylene and sealing with neutral gum. After staining, the proliferation of the mucus of the lung tissue is observed under an optical lens, the acidic mucus material or cells are blue, the neutral mucus material or cells are red, and the mixed mucus material or cells are purple. The positive expression area ratio was calculated using Image-Pro Plus 6.0 analysis software.
2.3.4 Immunofluorescence observation of lung tissue Clara Cell Secretion Protein (CCSP) expression
Dewaxing rat lung tissue paraffin sections, repairing antigens, sealing 3% hydrogen peroxide at 37 ℃ for 10 min in a dark place, sealing 5% BSA at room temperature for 30 min, adding CCSP primary antibody (1:100), incubating overnight at 4 ℃, adding fluorescent secondary antibody (1:500), incubating for 50 min in a dark place, counterstaining with DAPI, sealing with anti-fluorescence quenching sealing tablets, and observing under a confocal fluorescence microscope.
2.3.5 Immunohistochemical observation of lung tissue mucin 5AC (MUC 5 AC) and aquaporin 5 (AQP 5) expression
Rat lung tissue paraffin section, antigen restoration after dewaxing, then dripping peroxidase blocking agent, dripping MUC5AC primary antibody (1:2000), AQP5 primary antibody (1:2000), incubating overnight at 4 ℃, adding secondary antibody, incubating at 37 ℃ for 30 min, DAB color development, hematoxylin counterstain, alcohol dehydration, xylene transparency, neutral resin sealing, image analysis by Image-Pro Plus 6.0 software, and calculating positive expression area ratio.
2.3.6 Real-time PCR detection of MUC5AC and AQP5 mRNA expression in lung tissue
Taking rat lung tissue about 0.05 g, adding 1 mL Trizol, fully grinding and homogenizing in a sterilization homogenizer, extracting total RNA by using a chloroform extraction method, measuring the concentration of RNA and the absorbance at 260 and 280 nm by using an ultraviolet spectrophotometer, and calculating the purity. cDNA synthesis was performed in a 20. Mu.L system according to the reagent instructions, and the first strand of cDNA was synthesized by reacting at 42℃for 2 min, followed by heating at 37℃for 15 min and 85℃for 5 s, and then cooling to terminate the reaction. RT-PCR amplification was performed using 1. Mu.L of primer, using the GAPDH gene as an internal reference, and the primer sequences are shown in Table 1. Reaction conditions: 95. 40 cycles of 30 s,95 ℃, 5 s, 60 ℃, 34 s. PCR reactions and data collection were recorded on quantsudio real-time quantitative PCR systems, and relative mRNA expression of the target gene in each sample was calculated using the relative quantitative formula 2- Δct, where Δct value = target gene Ct value-GAPDH gene Ct value.
2.3.7 ELISA detection of TNF-alpha, IL-1 beta, MMP-9 content in alveolar lavage fluid (BALF) and IL-13 content in serum
Centrifuging an alveolar lavage fluid, taking a supernatant, adding 100 mu L of a sample or a standard substance into a detection hole, sequentially adding a biotinylated antibody working fluid, an enzyme conjugate working fluid, a substrate solution and a stop solution according to the incubation time and conditions of an ELISA kit instruction, detecting an Optical Density (OD) value at the wavelength of a nm enzyme labeling instrument, and calculating the contents of TNF-alpha, IL-1 beta, MMP-9 and IL-13 of the sample according to a standard curve.
2.4 statistical treatment
Analysis was performed using SPSS22.0 statistical software. Experimental dataThe representation shows that the method obeys normal distribution and has uniform variance, the comparison among multiple groups uses single factor variance analysis, and the comparison between every two groups uses an LSD method; non-parametric test for comparison between groups without normal distribution, pairwise comparison with pairwise multiple comparison, P<A difference of 0.05 is statistically significant.
3 results
3.1 general conditions
Compared with the normal group, the model group rats have audible and airway phlegm sound and cough, dry hair and reduced activity; compared with the model group, the drug group and ambroxol group of the invention have better glossiness of the rat hair and increased activity.
3.2 Effect of the drug of the present invention on model rat pulmonary tissue pathological changes
The lung tissue structure under the normal group rat lens is normal, and no pathological change is seen; alveolar space is expanded under a model group lens, alveolar walls are broken, bronchiole basement membrane is thickened, and more inflammatory cells infiltrate around the bronchiole basement membrane; the low, medium and high dose groups and ambroxol groups of the medicine have the alveolus structures tending to be regular, and the pathological changes are improved, so that the medium and high dose groups of the medicine are obvious. Model group alveolar mean intercept (MLI) increased significantly (p < 0.01) and Mean Alveolar Number (MAN) decreased significantly (p < 0.01) compared to normal group; compared with the model group, the medicine has obviously reduced MLI (p <0.05, p < 0.01) of low, medium and high doses and ambroxol group, and obviously increased MAN (p < 0.01); compared with ambroxol group, the MLI of the low, medium and high dose groups of the medicine has no significant difference (p > 0.05), the MAN of the low dose group of the medicine has significantly reduced (p < 0.01), and the MAN of the medium and high dose groups has no significant difference (p > 0.05). See fig. 1 and 2.
3.3 Effect of the drug of the present invention on model rat airway goblet cell metaplasia and mucus secretion
The research result shows that the airway and bronchi of the normal group rats have few cup-shaped cells, and no obvious mucus secretion exists in the airway. Compared with the normal group, the model group has the advantages that the airway of the rat has a large number of cup cells with blue dye particles to generate, the cup cells are prompted to secrete a large number of acid mucins, and the mucous secretion of the airway is obviously increased (P < 0.01); the results of the medium and high dose groups of the medicine have no significant difference (p > 0.05). See fig. 3, 4.
3.4 Effect of the drug of the invention on model rat lung tissue CCSP
The rat airway epithelium is damaged by combination of fumigation and LPS airway instillation, so that Clara cells are differentiated into goblet cells, and the medicine can relieve airway mucus hypersecretion by inhibiting the differentiation of Clara cells into goblet cells. The results show that the CCSP expression of the epithelial cells on the surface of the lung airway has positive expression, compared with a normal group, the CCSP expression of a model group is obviously reduced, and compared with the model group, the CCSP expression level of the medicine provided by the invention, a high-dose group and an ambroxol group is obviously increased. See fig. 5.
3.5 Effect of the drug of the invention on model rat pulmonary tissue MUC5AC, AQP5
The normal group showed a small amount of MUC5AC positive expression, and the model group showed significantly increased MUC5AC positive expression (P < 0.05) and significantly decreased AQP5 positive expression (P < 0.05) in airway epithelial cells as compared with the normal group. Compared with the model group, the MUC5AC positive expression of the low, medium and high dose groups and the ambroxol group of the medicine is obviously reduced (P < 0.05), the AQP5 positive expression is obviously increased (P < 0.05), and the high dose and the ambroxol group of the medicine are obvious. Compared with ambroxol group, the MUC5AC positive expression of the low-dose group of the medicine is obviously increased (p < 0.05), the medium-dose group and the high-dose group have no significant difference (p > 0.05), and the AQP5 positive expression of the low-dose group of the medicine is obviously reduced (p < 0.05); positive expression was significantly increased in medium and high dose groups (p < 0.05), see fig. 6, 7, 8.
3.6 The effect of the medicine on the expression of MUC5AC and AQP5 genes in lung tissue of model rat
Compared with the normal group, the lung tissue MUC5AC mRNA expression of the rat in the model group is obviously increased (P < 0.05), and the AQP5 mRNA expression is obviously reduced (P < 0.05); compared with the model group, the MUC5AC mRNA expression of the medium-dose group, the high-dose group and the ambroxol group of the medicine is obviously reduced (P < 0.05), and the low-dose group of the medicine has no statistical difference (P > 0.05); the expression of the AQP5 mRNA in the high-dose group of the medicine is obviously increased (P is less than 0.05), and the low-dose group, the medium-dose group and the ambroxol group of the medicine have no statistical difference (P is more than 0.05); compared with ambroxol group, the drug of the invention has no statistical difference (P > 0.05) between MUC5AC and AQP5 mRNA in low, medium and high dose groups, as shown in figure 9.
3.7 Effect of the drug of the invention on TNF- α, IL-1β, MMP-9 and IL-13 content in serum in model rat BALF
TNF- α, IL-1β and MMP-9 levels were significantly elevated in BALF in model group rats compared to normal group (P < 0.01); compared with the model group, the low-dose group of the medicine has no statistical difference (P > 0.05), and the levels of TNF-alpha, IL-1 beta and MMP-9 in the middle-dose group, the high-dose group and the ambroxol group of the medicine are obviously reduced (P < 0.01); compared with ambroxol group, the low-dose group of the medicine has obviously increased TNF-alpha and MMP-9 levels (P < 0.01), the dose group of the medicine has obviously reduced IL-1β levels (P < 0.01), the MMP-9 levels are obviously increased (P < 0.01), the high-dose group of the medicine has obviously reduced TNF-alpha and IL-1β levels (P < 0.01), and the MMP-9 levels are obviously increased (P < 0.01), as shown in figure 10.
The serum IL-13 levels were significantly elevated in rats in the model group compared to the normal group (P < 0.01); compared with the model group, the low-dose group of the medicine has no statistical difference (P > 0.05), and the IL-13 level of the middle-dose group, the high-dose group and the ambroxol group of the medicine is obviously reduced (P < 0.01); compared with ambroxol group, the IL-13 level of the low dose group of the medicine is obviously increased (P < 0.05); the IL-13 level in the high dose group of the present invention was significantly reduced (P < 0.01), see FIG. 11.
The medicine can maintain the airway mucus state balance by inhibiting MUC5AC expression and promoting AQP5 expression, and simultaneously reduces the lung inflammation by reducing the levels of inflammatory factors such as TNF-alpha, IL-1 beta, MMP-9, IL-13 in serum and the like in BLAF, thereby effectively improving the airway mucus high secretion state in the AECOPD acute exacerbation stage, relieving the illness state and providing basis for treating the AECOPD acute exacerbation stage by clinical traditional Chinese medicine.
Experimental example 2:
to further elucidate the effect of the drug of the present invention on improving the acute exacerbation phase of chronic obstructive pulmonary disease, the following experimental study was conducted using the tablet prepared in the method of example 1 (hereinafter referred to as the drug of the present invention or LHQK), which interferes with AECOPD airway mucus hypersecretion by modulating ciliated structure and function.
2. Materials and methods
2.1 Animals
Animal experiments were conducted according to the ethical guidelines of the ethical committee of the medical research institute (N2021162) in the northwest of the river. In this study, male Wistar rats (200-250 g, about 5-6 weeks old) were purchased from beijing velariwa laboratory animal technologies limited (beijing, china). Water is fed daily. Coat color, food intake and behavior were recorded.
2.2 grouping and administration
After one week of feeding, rats were randomly divided into 6 groups and placed in the laboratory at the animal center of the medical institute in Hebei, where the ambient temperature was 22.+ -. 2 ℃, the light/dark period was 12, and the humidity was 55.+ -. 5%.
The mice were divided into 6 groups, and 150 rats were treated with 3 doses according to the random digital schedule, including the normal control group, the CS+LPS control group, the LHQK-L, LHQK-M, LHQK-H group, and the ELP group. Rats of the control group and CS+LPS group were perfused with 0.5% sodium carboxymethyl cellulose (CMC) solution, and LHQK-L, LHQK-M, LHQK-H group rats were perfused with suspensions of 1.47g crude drug/kg/d, 2.93g crude drug/kg/d, and 5.86g crude drug/kg/d, respectively. Positive control rats were perfused with ELP (E.Eucalyptus capsule) (0.3 g/kg/d) suspension.
2.3 modeling
After 1 week of adaptive feeding, cigarette smoke in combination with lipopolysaccharide induced a model of chronic obstructive pulmonary disease in rats. Except for Normal Control (NC), rats were anesthetized with 2% sodium pentobarbital at day 1, day 14, 24 before drawing, and 200. Mu.L of 1 g/L LPS (sigma L2880) was administered, and no smoke was generated on the day of instillation. Rats were placed in a 100 cm x 70 cm x 40 cm stainless steel smoke box and exposed to smoke from 40 cigarettes of fire smoke from day 2 to day 90. Rats were exposed to smoke twice daily (1 h each at noon and afternoon), and allowed to rest for 2 days per week, and experimental models were established. CS exposure and dosing follow-up for 12 weeks.
2.4 hematoxylin and eosin (H & E)
Lung tissue was perfused with 4% paraformaldehyde solution to prevent alveolar collapse and ligate the trachea. Lung tissue was then fixed by embedding in paraformaldehyde solution, gradient solution dehydration, paraffin embedding, sectioning, hematoxylin eosin staining kit (H & E) staining (Beyotime, shanghai, china). Finally, the sections were photographed under a fully automated biological microscope (Leica DM6000B, wetzlar, germany). Average linear intercept (MLI) was measured to assess the extent of emphysema.
2.5 Scanning Electron Microscope (SEM)
Specimens (17-18 week old rats) were fixed with 2.5% glutaraldehyde and 1.5% paraformaldehyde in 0.1M sodium phosphate buffer, pH 7.3, at room temperature for 3 hours, and then 2 hours in 2% osmium tetroxide 0.1 sodium phosphate buffer. After dehydration in gradient ethanol, the samples for Scanning Electron Microscopy (SEM) were dried in a critical point dryer (poled, woad, uk), mounted on sample roots, and coated with gold-palladium in a cold sputter coater (Fisons Instruments Uckfield, uk). The specimens were examined using a scanning electron microscope DSM 960 (Zeiss Oberkochen, germany). Finally, the morphology and length of the tracheal epithelial cilia were observed by scanning electron microscopy. At least 3 cilia on each ciliated cell in each image (n=3-5 images per sample) were measured by ImageJ software tool, and the average length of cilia in SEM images of the culture (x 1000 magnification) was calculated. The cilia length distribution was determined using a frequency histogram distribution tool in GraphPad Prism.
2.6 immunofluorescence analysis
Rat trachea was fixed with 4% paraformaldehyde and 5 μm paraffin sections. The trachea is dewaxed for antigen retrieval, PBS is cleaned, hydrogen peroxide is incubated for 10 min at 37 ℃, PBS is cleaned for 3 times, and 5% BSA is blocked for 30min at room temperature. The trachea was incubated with beta-Tubulin IV (abcam, 1:500) overnight at 4 ℃. The trachea was washed with PBS and incubated with secondary antibody (gold Anti-Rabbit IgG H & L (DYlight 488, proteintech, 1:200) for 50min at room temperature after three more washes with PBS, the nuclei were stained with DAPI (Solarbio, beijin, china) for 10 min.
2.7Western blot analysis
Protein was extracted from rat lung tissue using RIPA lysis buffer containing the protease inhibitor PMSF. Protein concentration was then determined using BCA protein assay kit (Biyuntian, china). An appropriate amount of 5 Xprotein loading buffer, 100 XC, was added to the sample and boiled for 10 minutes. After cooling, the proteins were separated on a 4-20% SDS-PAGE gel (GenScript Biotech Corporation, china) and transferred to PVDF (Life Sciences, mexico). The membrane was blocked with an odxe blocking buffer (LI-COR, lincoln USA) for 1 hour at 37% C and incubated overnight with primary antibody (beta-Tubulin IV, abcam, 1:500) at 4% C. After 3 washes with TBST (10 min each), the membranes were further incubated with secondary antibodies (goat anti-rabbit IgG H & L) for 1 hour at 37C. After 3 more washes with TBST, the membrane was scanned with an Ordersai imager (LI-COR, lincoln USA). GAPDH is used as an internal reference.
2.8 analysis of the frequency of cilia swing of the tracheal annulus
Rats were anesthetized with pentobamidine, the trachea was removed and placed in DMEM medium. The tracheal ring (main trachea) was cut to about 0.5mm thickness with a scalpel and equilibrated in DMEM for 20-30 minutes. Then, 3-5 different fields of view were randomly selected under a high-speed camera, an inverted microscope and a 40-fold phase difference objective to record cilia motion. The time is 2.0-3.0 seconds, and the rate is 200-250 frames/second. The resulting image was imported into ImageJ, 3-6 regions of interest (ROIs) were selected, and the average gray values were measured within the ROI range of each frame. The variation of the gray intensity of the individual regions of interest is caused by repeated movements of the cilia, as shown. The beat period is calculated by dividing the number of complete beats by the time spent, with the mean ± standard deviation expressed in Hz.
2.9 in vitro ciliated cell cilia swing frequency analysis
Euthanasia was performed on 5 Wistar rats, 70% ethanol was sprayed on the neck portion, and the surface of the abdomen was cut laterally in the neck. Subcutaneous fat is removed, exposing the trachea. The adherent adipose tissue was harvested and washed and spread. The treated tracheal tissue was placed in Pronase E (100 mg/ml; from Streptomyces griseus, MCE, hy114158 a), DNase I (Solarbio, D8071) and DMEM/F12 (gibco, C11330500 BT) and digested overnight at 4℃for 18h. Then, the airway epithelial cells were gently dispersed with 10% Fetal Bovine Serum (FBS) upside down 15 times, the mixture was collected into a new tube, the collection medium containing 10% fetal bovine serum was added, and the mixture was gently inverted upside down 20-30 times, so as to obtain more epithelial cells, the above procedure was repeated twice, and all the mixture was collected into the same tube. The trachea is discarded. The mixture was centrifuged at 500g at 4℃for 10min. The supernatant was carefully discarded and the bottom cell pellet was resuspended in 2ml of culture medium. The suspension was placed in a 12-well plate and 20-30 ciliated cells were randomly selected under a high-speed camera, an inverted microscope and a phase contrast objective (40 x). The shooting criteria and statistical analysis are the same as for the tracheal rings CBF.
2.10 Transmission Electron Microscope (TEM)
Samples (17-18 week old rats) were sectioned into small sections (1 x 1 mm) using Transmission Electron Microscopy (TEM) and fixed in 2.5% glutaraldehyde (ph=7). 4) Standing at 4deg.C for 6-8 hr. Washed and fixed in 2% OsO4 for 1 hour at 4 ℃. Tissues were embedded in alalite CY212 after increasing ethanol concentration. Cut half sheet (1 μm) and stained with toluidine blue. And cutting ultrathin sections (60-80 nm), and dyeing with uranyl acetate and alkaline lead citrate.
2.11 cilia direction analysis
At 15000 magnification, at least 10 cilia cross-sections were captured per field of view, with the center pair clearly visible to measure cilia direction within the cilia shaft. On each image, a line was drawn on the center pair of each cross section, and the angle of each line was measured with a computer (vertical upward=0°; horizontal rightward=90°; vertical downward=180°). Thus, in each image, the directional angle of each cilia is obtained, and the standard deviation of the axial angle of each cilia is calculated. The mean standard deviation of the cilia axis represents an overall measure of cilia disorientation in the subject. Each animal was given 5 pictures and each group was given 3 animals at random.
2.12 cilia ultrastructural analysis
3 animals were randomly selected for each group, and 3-5 images were randomly selected for each animal. The total number of cilia and the number of abnormal cilia were counted in a TEM image at 15000x, and the percentage of abnormal cilia was calculated. Cilia defects include ciliated membrane vesicles, loss of power arms, microtubule defects, composite cilia, and giant cilia.
2.13 statistical analysis
All results are expressed as mean ± standard deviation and analyzed using SPSS 26.0 software. The data sets were compared using one-way analysis of variance (ANOVA). In all analyses, P < 0.05 was statistically significant and P < 0.01 was highly statistically significant. In addition, all graphics were created using GraphPad Prism (8.0) software.
3. Results
3.1 LHQK can alleviate pathological damage of pulmonary tissue of AECOPD rat
Lung tissue pathology was assessed using H & E staining (fig. 12A). The results show that the difference is statistically significant in the AECOPD model group under the microscope compared to the control group. The alveolar septum is thickened, inflammatory cells are increased, the increased alveoli are fused to form lung large bubbles, and the bronchial ciliated columnar epithelial cells are partially shed, denatured and necrotized, and goblet cells are increased, which indicates that the model is successfully prepared. The control group has complete and uniform alveolar structure, clear alveolar space and fewer inflammatory cells in the alveolar space. Compared with the model group, the LHQK group and the positive drug group have reduced alveolus quantity, partial alveolus is combined into large alveolus, small amount of inflammatory change occurs in the alveolus, and the shedding, the denaturation and the necrosis of bronchial epithelial cells are reduced.
Lung tissue pathologic injury was assessed by measuring average alveolar intercept (fig. 12B). The results showed that the average alveolar intercept was significantly higher than the control (P < 0.01). The average alveolar intercept of LHQK and ELP groups was significantly smaller than that of cs+lps group (P < 0.01). The above results indicate that cs+lps exacerbates pathological lesions in lung tissue in AECOPD rats, whereas the medium, high and ELP groups of LHQK reverse this change, with the dose effect of LHQK-M being most pronounced.
3.2 LHQK can improve CS+LPS-induced AECOPD rat airway epithelial cilia morphology changes
Airway epithelial cilia morphology changes were assessed by tracheal H & E staining (fig. 13A). The results show that the airway epithelium of the cs+lps group is shortened and deleted compared to the control group, whereas the airway epithelium of the LHQK, high dose group and ELP group is slightly damaged, the cilia still being aligned and a small number of deletions.
To further observe changes in morphology of airway epithelial cilia, airway epithelial cilia morphology was assessed by Scanning Electron Microscopy (SEM) cross-section (fig. 13B). The results show that the tracheal epithelium of the CS+LPS group has sparse cilia, shortened cilia length, disordered cilia arrangement, falling cilia, inconsistent swing, partial cilia fracture and more reticulate secretion attached to the cilia surface. The degree of airway epithelialization of LHQK, medium and high dose groups and ELP groups is increased, the cilia length is obviously increased, cilia are orderly arranged, the swinging directions of cilia are consistent, and no obvious reticular secretion is seen on the cilia surface.
3.3 LHQK reduces CS+LPS induced AECOPD rat cilia shortening
Cs+lps may shorten AECOPD rat ciliary length and LHQK may increase AECOPD rat ciliary length. To further investigate the change in cilia length, we used scanning electron microscopy longitudinal sections (fig. 14) to evaluate cilia length. The results show that the cilia length of the cs+lps group is significantly shortened compared to the control group. The cilia length was significantly increased in LHQK, both in the medium, high dose and ELP groups.
3.4 LHQK increases reduction of airway epithelial cilia under CS+LPS action
Cs+lps may decrease airway epithelial cilia, while LHQK may increase airway epithelial cilia number. To further investigate changes in cilia number, immunofluorescence and Western Blot were used to detect expression of the cilia marker β -Tubulin IV protein. Immunofluorescence (FIG. 15A) and Western Blot (FIGS. 15B-C) results showed that the CS+LPS group beta-Tubulin IV expression was significantly down-regulated (P < 0.01) compared to the control group. In LHQK, high dose and ELP groups beta-Tubulin IV expression was up-regulated (P < 0.05) compared to CS+LPS group.
3.5 LHQK significantly improves the reduced cilia beat frequency of cs+lps
Cs+lps reduced CBF in AECOPD rats, while LHQK ameliorated this injury. The high speed camera captures video images, which are analyzed with Image J software (fig. 16A-B), and the tracheal annulus cilia CBF is evaluated. CBF was significantly reduced in cs+lps group compared to control group (p < 0.01). The CBF was significantly improved in LHQK, in the high dose group and in the ELP group compared to the cs+lps group (P < 0.01).
To observe the CBF of cilia in vitro, we assessed CBF of individual cilia cells of each group using low temperature enzymatic digestion to acutely isolate cilia cells of AECOPD rats. The cs+lps group single ciliated cells CBF was significantly reduced compared to the control group (P < 0.01). The medium, high dose and ELP groups of LHQK significantly improved single ciliated CBF (P < 0.01) compared to the cs+lps group. The results of in vitro and in vivo studies were consistent. The above results indicate that cs+lps group can reduce CBF in and out of AECOPD rats, while LHQK can significantly improve CBF in and out of AECOPD rats.
3.6 LHQK can improve cilia ultrastructural damage caused by CS+LPS
CS+LPS causes cilia ultrastructural damage, and LHQK can improve cilia ultrastructural damage, and cilia ultrastructural is observed by transmission electron microscopy. The cilia ultrastructure is shown in fig. 17. The results showed that the cs+lps group had a smaller number and uneven distribution of cilia structures compared to the control group, most of the structures were significantly damaged, the cilia membrane damage disintegrated, and cilia membrane blebs, central microtubules or outer Zhou Weiguan shift significantly increased. While the number of cilia in the medium, high dose and positive drug groups of LHQK is significantly increased. The cilia structure was essentially intact, with no apparent membrane damage or disintegration. Ciliated membrane vesicles, central microtubules or outer Zhou Weiguan displacement are significantly reduced. The above results indicate that the cilia ultrastructural lesions of the CS+LPS group are significantly aggravated, while LHQK can reverse the lesions.
3.7 CS+LPS may cause the cilia to be non-uniform in direction and LHQK may be improved.
The cilia direction was assessed from the TEM photograph by measuring the angle between the plane defined by the central tubule and the reference lead. The cilia direction is shown in fig. 18. The results showed that the ciliated direction of the cs+lps group was disordered compared to the blank group. The cilia direction of the medium, high dose and positive drug groups in LHQK are relatively consistent. These results indicate that cs+lps has a damaging effect on cilia direction, while LHQK has an improving effect on cilia direction.
By studying the structure and function of cilia in AECOPD rats, it was found that the protective effect of the drug of the present invention on AECOPD rats may be related to the structural and functional changes of cilia, which play an important role in clearing airway mucus.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, or alternatives falling within the spirit and principles of the invention.
Claims (22)
1. The application of the traditional Chinese medicine composition in preparing the medicine for treating the acute exacerbation stage of the chronic obstructive pulmonary disease is characterized in that the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 52-86 of ephedra; gypsum 194-324; fructus forsythiae 194-324; 78-130 parts of radix scutellariae; white mulberry root bark 194-324; 78-130 parts of fried bitter apricot kernel; 78-130 parts of radix peucedani; 78-130 parts of pinellia ternate; 78-130 parts of dried orange peel; 78-130 parts of fritillary bulb; 78-130 parts of burdock; 78-130 parts of lonicera japonica; 39-65 parts of rheum officinale; radix Platycodi 46-76; 39-65 parts of liquorice.
2. The use of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 52; gypsum 324; fructus forsythiae 194; radix Scutellariae 78; cortex Mori 194; parching semen Armeniacae amarum 130; radix Peucedani 78; pinellia ternate 130; dried orange peel 78; bulbus Fritillariae Thunbergii 78; fructus Arctii 130; flos Lonicerae 130; rhubarb 39; radix Platycodi 76; licorice 65.
3. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 86; gypsum 194; fructus forsythiae 324; radix Scutellariae 130; cortex Mori 324; parching semen Armeniacae amarum 78; radix Peucedani 130; pinellia tuber 78; dried orange peel 130; bulbus Fritillariae Thunbergii 130; burdock 78; flos Lonicerae 78; rhubarb 65; radix Platycodi 46; licorice 39.
4. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: ephedra 69; gypsum 259; fructus forsythiae 259; radix Scutellariae 104; cortex Mori 259; parching semen Armeniacae amarum 104; radix Peucedani 104; pinellia ternate 104; dried orange peel 104; bulbus Fritillariae Thunbergii 104; fructus Arctii 104; flos Lonicerae 104; rhubarb 52; radix Platycodi 61; licorice 52.
5. The application of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: herba Ephedrae 55; gypsum 254; fructus forsythiae 318; radix Scutellariae 107; white mulberry root bark 203; a fried bitter almond 107; radix Peucedani 82; pinellia ternate 105; dried orange peel 84; bulbus Fritillariae Thunbergii 125; burdock 122; flos Lonicerae 113; rhubarb 42; radix Platycodi 60; licorice root 50.
6. Use according to any one of claims 1-5, characterized in that the active ingredient of the medicament is made by the steps of:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 40-70% ethanol for 2 times, each for 1-4 hr, adding 8-10 times of the extractive solution for the first time and 6-9 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.14-1.16 at 60deg.C;
C. weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for two times, 1-4 hours each time, adding 9-11 times of the weight of the first time and 7-9 times of the weight of the second time, merging decoction, filtering, decompressing filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.14-1.16 measured by heat at 60 ℃, merging with the clear paste obtained in the step B for standby;
the fine powder obtained in the step A and the combined fluid extract obtained in the step C jointly form the active ingredient of the pharmaceutical composition.
7. The use according to any one of claims 1 to 5, characterized in that the pharmaceutical dosage form is a tablet, capsule, powder, granule, oral liquid, pill, tincture, syrup, suppository, gel, spray or injection.
8. Use according to claim 7, characterized in that the tablet is made up of the following steps:
A. weighing Bulbus Fritillariae Thunbergii according to the proportion of the prescription, and pulverizing into fine powder for use;
B. weighing herba Ephedrae, fructus forsythiae, parched semen Armeniacae amarum, rhizoma Pinelliae, fructus Arctii, and radix et rhizoma Rhei, reflux extracting with 50% ethanol for 2 times and 3 hr each time, adding 10 times of the extractive solution for the first time and 6 times of the extractive solution for the second time, mixing the extractive solutions, filtering, recovering ethanol from the filtrate under reduced pressure, concentrating to obtain fluid extract with relative density of 1.15 at 60deg.C;
C. weighing gypsum, white mulberry root-bark, peucedanum root, dried orange peel, lonicera japonica, platycodon grandiflorum and liquorice according to the proportion of the prescription, adding water and decocting for 2 hours each time, adding 10 times of the weight for the first time and 7 times of the weight for the second time, merging the decoctions, filtering, decompressing the filtrate, recovering ethanol, concentrating to obtain clear paste with the relative density of 1.15 measured by heat at 60 ℃, merging the clear paste obtained in the step B for standby;
D. c, spraying and drying the combined fluid extract obtained in the step C, and collecting spraying powder for later use;
E. the weight proportion of the raw materials required by tabletting is as follows:
step D, spraying powder 282.6; the fine powder 101 obtained in the step A; 12.5 parts of sodium carboxymethyl starch; microcrystalline cellulose 9.0; 2.25 parts of magnesium stearate, adding starch, and making into tablet by conventional preparation method.
9. The use according to any one of claims 1 to 5, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for inhibiting the differentiation of Clara cells into goblet cells.
10. The use according to any one of claims 1 to 5, characterized in that the use of the Chinese medicinal composition for the preparation of a medicament for increasing CCSP protein expression is described.
11. The use according to any one of claims 1 to 5, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for promoting the expression of AQP5 protein or AQP5 mRNA.
12. The use according to any one of claims 1 to 5, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for reducing the expression of MMP-9 or IL-13 factor.
13. The use according to any one of claims 1-5, characterized in that the use of the traditional Chinese medicine composition for the preparation of a medicament for treating lung injury.
14. The use according to any one of claims 1-5, characterized in that the use of the traditional Chinese medicine composition for the preparation of a medicament for protecting the cilia structure of airway epithelium.
15. The use according to claim 14, characterized by the use of said Chinese medicinal composition for the preparation of a medicament for increasing cilia length.
16. The use according to claim 14, characterized by the use of said Chinese medicinal composition for the preparation of a medicament for increasing the quantity of cilia.
17. The use according to claim 16, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for up-regulating the expression of β -Tubulin IV protein.
18. The use according to claim 14, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for improving cilia direction.
19. The use according to claim 14, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for protecting cilia from ultrastructural damage.
20. The use according to any one of claims 1-5, characterized in that the use of the traditional Chinese medicine composition for the preparation of a medicament for protecting airway cilia function.
21. The use according to claim 20, characterized by the use of said Chinese medicinal composition for the preparation of a medicament for increasing cilia beat frequency.
22. The use according to any one of claims 1-5, characterized in that the use of said Chinese medicinal composition for the preparation of a medicament for improving airway hypersecretion in patients suffering from acute exacerbation of chronic obstructive pulmonary disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211627569.1A CN116059293B (en) | 2022-12-17 | 2022-12-17 | Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211627569.1A CN116059293B (en) | 2022-12-17 | 2022-12-17 | Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116059293A CN116059293A (en) | 2023-05-05 |
CN116059293B true CN116059293B (en) | 2024-04-16 |
Family
ID=86176033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211627569.1A Active CN116059293B (en) | 2022-12-17 | 2022-12-17 | Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116059293B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101549060A (en) * | 2008-04-01 | 2009-10-07 | 河北以岭医药研究院有限公司 | Medicament containing gnetales for treating bronchitis and preparation method thereof |
CN101564460A (en) * | 2008-04-24 | 2009-10-28 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic obstructive pulmonary disease |
CN102370783A (en) * | 2010-08-19 | 2012-03-14 | 北京以岭药业有限公司 | Application of traditional Chinese drug composition in preparation of drugs for treating lung injury caused by smoking |
CN112007096A (en) * | 2020-10-16 | 2020-12-01 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing chronic obstructive pneumonia |
CN113384647A (en) * | 2020-03-11 | 2021-09-14 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury |
-
2022
- 2022-12-17 CN CN202211627569.1A patent/CN116059293B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101549060A (en) * | 2008-04-01 | 2009-10-07 | 河北以岭医药研究院有限公司 | Medicament containing gnetales for treating bronchitis and preparation method thereof |
CN101564460A (en) * | 2008-04-24 | 2009-10-28 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparing medicament for treating chronic obstructive pulmonary disease |
CN102370783A (en) * | 2010-08-19 | 2012-03-14 | 北京以岭药业有限公司 | Application of traditional Chinese drug composition in preparation of drugs for treating lung injury caused by smoking |
CN113384647A (en) * | 2020-03-11 | 2021-09-14 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating acute lung injury |
CN112007096A (en) * | 2020-10-16 | 2020-12-01 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing chronic obstructive pneumonia |
Non-Patent Citations (1)
Title |
---|
清金化痰汤对COPD模型大鼠肺组织中性粒细胞弹性蛋白酶及黏蛋白5AC表达的影响;陈英;冯淬灵;李根茂;葛东宇;王骏;李春盈;姚小芹;;吉林中医药(01);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116059293A (en) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2520745C2 (en) | Therapeutic composition for treating bronchitis and method for preparing it | |
CN103405699B (en) | Beverage for preventing and treating respiratory diseases caused by haze and preparation method thereof | |
CN111888435A (en) | Anti-coronavirus traditional Chinese medicine composition and application thereof in treating inflammation | |
WO2022057360A1 (en) | Pharmaceutical composition for use preventing and curing respiratory diseases in winter | |
CN112007096A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing chronic obstructive pneumonia | |
CN116059293B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating acute exacerbation stage of chronic obstructive pulmonary disease | |
KR102188416B1 (en) | Complex Medicines for Improving Respiratory Inflammation Caused Fine Dust | |
CN113940945A (en) | Application of houttuynia polysaccharide in preparation of medicine for preventing and treating inflammatory bowel disease | |
CN107485614A (en) | Application of the momordica grosvenori alcohol in anti-hepatic fibrosis medicines | |
WO2017173611A1 (en) | Pharmaceutical product for treating tumor and combined immune defect, and preparation and application thereof | |
CN111097002A (en) | Traditional Chinese medicine composition for clearing and nourishing throat and preparation method thereof | |
CN111920905B (en) | Traditional Chinese medicine composition and application thereof | |
CN112472749A (en) | Traditional Chinese medicine granules for treating chronic obstructive pulmonary disease in stationary phase and preparation method and application thereof | |
CN106924448B (en) | Pharmaceutical composition for treating wind-heat type common cold and preparation method thereof | |
CN111067891A (en) | Application of sanggenon C in improvement or treatment of pulmonary fibrosis | |
CN110575505A (en) | Medicine for treating acute bronchitis and acute attack of chronic bronchitis and preparation method and application thereof | |
WO2008095429A1 (en) | A glycoprotein for treating chronic obstructive pulmonary diseases | |
CN115845021B (en) | A Chinese medicinal composition for preventing and treating pulmonary fibrosis, and its preparation method | |
CN115137764B (en) | Application of fructus zizyphi spinosae extract in preparation of chronic obstructive pulmonary disease medicine and pharmaceutical composition | |
CN116077609B (en) | Yellow thick antidiarrheal quick-release pellet for treating IBD and IBS and preparation method thereof | |
CN115364129B (en) | Application of herba Pileae Scriptae or its extract, and preparation for clearing heat and relieving inflammation in preparation of anti-coronavirus medicine and preparation method thereof | |
EA025133B1 (en) | Method for producing dry extracts | |
AU2021200606B2 (en) | Application of phlegmyheatclear in preparation of drug for treatment of acute exacerbation of chronic obstructive pulmonary disease | |
CN115025127B (en) | Application of poecilobdella manillensis in preparation of medicine for treating chronic obstructive pulmonary disease and traditional Chinese medicine preparation | |
CN113876844A (en) | Pure traditional Chinese medicine Tibetan medicine for treating chronic tracheitis and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |